Anti-CDH6 Antibody Drug Conjugate Linker Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers resistant to tyrosine kinase inhibitors, serine/threonine kinase inhibitors, and chemotherapy lack effective methods, particularly for cancers expressing high levels of CDH6, where existing CDH6-directed antibody-drug conjugates like DS-6000a have not been approved and require improved safety and efficacy.
Innovation Solution
Development of an antigen-binding protein with high sensitivity and specificity for CDH6, capable of binding with a KD value below 3.1×10−9M and internalization by CDH6-expressing cells, potentially used in antibody drug conjugates with a specific linker structure to deliver cytotoxic agents effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CDH6-directed antibody drug conjugates like DS-6000a are used, then CDH6-targeted therapy can be provided, but safety and efficacy have not been established and approval has not been obtained
Solution Approach 1:
The patent changes critical parameters of the antibody-drug conjugate by using a humanized anti-CDH6 IgG1 monoclonal antibody with specific affinity (KD value below 3.1×10−9M) and optimizing the linker-drug payload combination. These parameter optimizations are intended to establish demonstrable safety and efficacy for regulatory approval.
Solution Approach 2:
The patent creates a humanized version of the anti-CDH6 antibody, copying and adapting the binding specificity while optimizing for human physiological conditions. This humanized approach (CL069707-H1L1) replaces the original chimeric antibody to improve safety profile and enable clinical approval.
2Measurement precision
If high-affinity anti-CDH6 antibodies are developed, then binding sensitivity and specificity are improved, but development complexity and validation requirements increase
Solution Approach 1:
The patent optimizes the affinity parameter by selecting and characterizing antibodies with KD values below 3.1×10−9M, achieving high binding sensitivity. This parameter optimization is supported by standardized ELISA assay protocols that validate binding characteristics without requiring overly complex measurement systems.
Solution Approach 2:
The patent divides the validation process into distinct segments: ELISA binding assays, cell-based internalization studies, and in vivo efficacy models. This segmentation allows systematic evaluation of each parameter (binding affinity, cellular uptake, therapeutic effect) independently, reducing overall development complexity.
3Productivity
If antibody-drug conjugates are developed for cancer treatment, then targeted delivery of cytotoxic agents is achieved, but attrition during clinical development remains high
Solution Approach 1:
The patent optimizes critical parameters including antibody isotype (IgG1), linker chemistry (tetrapeptide-based cleavable linker), and payload selection (topoisomerase I inhibitor). These parameter changes are designed to overcome common failure modes in ADC development and improve clinical development success rate.
Solution Approach 2:
The patent uses a cleavable linker as an intermediary between the antibody and cytotoxic payload. This linker (tetrapeptide-based) enables controlled release of the active drug inside the target cell while maintaining stable conjugation during circulation, addressing key challenges in ADC clinical development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antigen-binding protein achieves excellent antitumor effects and safety by specifically targeting CDH6-expressing cancer cells, providing a promising treatment for CDH6-positive tumors, including renal cell carcinoma, ovarian cancer, and other types, with potential for improved clinical outcomes.
Implementation Method 1
capable of binding to the CDH6 protein with a KD value below about 3.1×10−9M in an ELISA assay
Implementation Method 2
having capable of being internalized by an CDH6-expressing cell upon binding to CDH6
Data Source
AI summary
Provided is an antigen-binding protein having the following properties: (a) specifically binding to CDH6, and (b) having the activity of being internalized into CDH6-expressing cells by binding to CDH6. Further provided an immunoconjugate comprising an antibody or antigen binding fragment thereof that specifically binds to CDH6 and has internalization activity, a pharmaceutical product comprising the immunoconjugate and having therapeutic effects on a tumor, a method for treating a tumor using the immunoconjugate or the pharmaceutical product, and the like.